The federal government notified drug makers Lilly, Novo Nordisk, and Sanofi in court papers on Friday about its withdrawal of its 340B contract pharmacy legal advisory opinion, in connection with AstraZeneca’s contract pharmacy lawsuit. It said the withdrawal does not affect enforcement proceedings against them for denying 340B pricing on drugs when covered entities use contract pharmacies.
Last week Wednesday, the federal judge hearing AstraZeneca’s suit ruled that the 340B statute is silent on contract pharmacy. The government responded on Friday by withdrawing the advisory opinion.
The federal government notified drug makers Lilly, Novo Nordisk, and Sanofi in court papers on Friday about its withdrawal of its 340B contract pharmacy legal advisory opinion, in connection with AstraZeneca’s contract pharmacy lawsuit. It said the withdrawal does not affect enforcement proceedings against them for denying 340B pricing on drugs when covered entities use contract pharmacies.
Last week Wednesday, the federal judge hearing AstraZeneca’s suit ruled that the 340B statute is silent on contract pharmacy. The government responded on Friday by withdrawing the advisory opinion.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
